Literature DB >> 21426320

Generation and characterization of a humanized PPARδ mouse model.

B Gross1, N Hennuyer, E Bouchaert, C Rommens, D Grillot, H Mezdour, B Staels.   

Abstract

BACKGROUND AND
PURPOSE: Humanized mice for the nuclear receptor peroxisome proliferator-activated receptor δ (PPARδ), termed PPARδ knock-in (PPARδ KI) mice, were generated for the investigation of functional differences between mouse and human PPARδ and as tools for early drug efficacy assessment. EXPERIMENTAL APPROACH: Human PPARδ function in lipid metabolism was assessed at baseline, after fasting or when challenged with the GW0742 compound in mice fed a chow diet or high-fat diet (HFD). KEY
RESULTS: Analysis of PPARδ mRNA levels revealed a hypomorph expression of human PPARδ in liver, macrophages, small intestine and heart, but not in soleus and quadriceps muscles, white adipose tissue and skin. PPARδ KI mice displayed a small decrease of high-density lipoprotein-cholesterol whereas other lipid parameters were unaltered. Plasma metabolic parameters were similar in wild-type and PPARδ KI mice when fed chow or HFD, and following physiological (fasting) and pharmacological (GW0742 compound) activation of PPARδ. Gene expression profiling in liver, soleus muscle and macrophages showed similar gene patterns regulated by mouse and human PPARδ. The anti-inflammatory potential of human PPARδ was also similar to mouse PPARδ in liver and isolated macrophages. CONCLUSIONS AND IMPLICATIONS: These data indicate that human PPARδ can compensate for mouse PPARδ in the regulation of lipid metabolism and inflammation. Overall, this novel PPARδ KI mouse model shows full responsiveness to pharmacological challenge and represents a useful tool for the preclinical assessment of PPARδ activators with species-specific activity.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21426320      PMCID: PMC3171871          DOI: 10.1111/j.1476-5381.2011.01359.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   9.473


  48 in total

1.  Humanized xenobiotic response in mice expressing nuclear receptor SXR.

Authors:  W Xie; J L Barwick; M Downes; B Blumberg; C M Simon; M C Nelson; B A Neuschwander-Tetri; E M Brunt; P S Guzelian; R M Evans
Journal:  Nature       Date:  2000-07-27       Impact factor: 49.962

2.  Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

Authors:  Dennis L Sprecher; Christine Massien; Greg Pearce; Andrew N Billin; Itay Perlstein; Timothy M Willson; David G Hassall; Nicolas Ancellin; Scott D Patterson; David C Lobe; Tony G Johnson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-16       Impact factor: 8.311

3.  PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents.

Authors:  H Keller; P R Devchand; M Perroud; W Wahli
Journal:  Biol Chem       Date:  1997-07       Impact factor: 3.915

4.  A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.

Authors:  W R Oliver; J L Shenk; M R Snaith; C S Russell; K D Plunket; N L Bodkin; M C Lewis; D A Winegar; M L Sznaidman; M H Lambert; H E Xu; D D Sternbach; S A Kliewer; B C Hansen; T M Willson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

5.  Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

Authors:  Ulf Risérus; Dennis Sprecher; Tony Johnson; Eric Olson; Sandra Hirschberg; Aixue Liu; Zeke Fang; Priti Hegde; Duncan Richards; Leli Sarov-Blat; Jay C Strum; Samar Basu; Jane Cheeseman; Barbara A Fielding; Sandy M Humphreys; Theodore Danoff; Niall R Moore; Peter Murgatroyd; Stephen O'Rahilly; Pauline Sutton; Tim Willson; David Hassall; Keith N Frayn; Fredrik Karpe
Journal:  Diabetes       Date:  2007-11-16       Impact factor: 9.461

6.  PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages.

Authors:  John S Welch; Mercedes Ricote; Taro E Akiyama; Frank J Gonzalez; Christopher K Glass
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-09       Impact factor: 11.205

7.  Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver.

Authors:  Linda M Sanderson; Tatjana Degenhardt; Arjen Koppen; Eric Kalkhoven; Beatrice Desvergne; Michael Müller; Sander Kersten
Journal:  Mol Cell Biol       Date:  2009-10-05       Impact factor: 4.272

Review 8.  Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation.

Authors:  Vishnu Ji Ram
Journal:  Prog Drug Res       Date:  2003

9.  The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.

Authors:  Uwe Dressel; Tamara L Allen; Jyotsna B Pippal; Paul R Rohde; Patrick Lau; George E O Muscat
Journal:  Mol Endocrinol       Date:  2003-10-02

10.  Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol.

Authors:  François Briand; Snehal U Naik; Ilia Fuki; John S Millar; Colin Macphee; Max Walker; Jeffrey Billheimer; George Rothblat; Daniel J Rader
Journal:  Clin Transl Sci       Date:  2009-04       Impact factor: 4.438

View more
  5 in total

Review 1.  Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.

Authors:  Jeffrey M Peters; Jennifer E Foreman; Frank J Gonzalez
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 2.  Genomically humanized mice: technologies and promises.

Authors:  Anny Devoy; Rosie K A Bunton-Stasyshyn; Victor L J Tybulewicz; Andrew J H Smith; Elizabeth M C Fisher
Journal:  Nat Rev Genet       Date:  2011-12-16       Impact factor: 53.242

3.  Conditional Expression of Human PPARδ and a Dominant Negative Variant of hPPARδ In Vivo.

Authors:  Larry G Higgins; Wojciech G Garbacz; Mattias C U Gustafsson; Sitheswaran Nainamalai; Peter R Ashby; C Roland Wolf; Colin N A Palmer
Journal:  PPAR Res       Date:  2012-03-21       Impact factor: 4.964

4.  Systematic target function annotation of human transcription factors.

Authors:  Yong Fuga Li; Russ B Altman
Journal:  BMC Biol       Date:  2018-01-10       Impact factor: 7.431

5.  Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors.

Authors:  Stéphane Mandard; David Patsouris
Journal:  PPAR Res       Date:  2013-03-07       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.